title: Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia.
abstract: For the past half century, thiopurines have earned themselves a reputation as effective anti-cancer and immunosuppressive drugs. Thiopurine S-methyltransferase (TPMT) is involved in the metabolism of all thiopurines and is one of the main enzymes that inactivates mercaptopurine. 6-MP is now used as a combination therapies for maintenance therapy of children with acute lymphocytic leukemia (ALL). In all patients receiving mercaptopurine, there is a risk of bone marrow suppression. TPMT activity is inherited as a monogenic, co-dominant trait. More than 25 variants are known. Genetic testing is available for several TPMT variant alleles. Most commonly TPMT*2, *3A, and *3C are tested for, which account for >90% of inactivating alleles. Differences in DNA that alter the expression or function of proteins that are targeted by drugs can contribute significantly to variation in the responses of individuals.Genotyping may become part of routine investigations to help clinicians tailor drug treatment effectively. This success is mainly due to the development of combination therapies and stratification of patients according to risk of treatment failure and relapse, rather than the discovery of new drugs. The aim of this study was to investigate the effect of genotype or methyltransferase enzyme activity before starting therapy in children with ALL. This can prevent the side effect of thiopurine drugs. In fact, the common polymorphism of this enzyme in population could be a prognostic factor in relation to drug use and treatment of patients with ALL.
authors.affiliation: M.S.c student of medical genetics, Zanjan University of Medical Science, Zanjan,Iran.
authors.forename: F
authors.initials: F
authors.lastname: Azimi
authors.affiliation: M.S.c student of medical genetics, Zanjan University of Medical Science, Zanjan,Iran.
authors.forename: M
authors.initials: M
authors.lastname: Jafariyan
authors.affiliation: PhD student of molecular medicine, Zanjan University of Medical Science, Zanjan,Iran.
authors.forename: S
authors.initials: S
authors.lastname: Khatami
authors.affiliation: Assistant professor in hematology, Zanjan University of Medical Science, Zanjan,Iran.
authors.forename: Y
authors.initials: Y
authors.lastname: Mortazavi
authors.affiliation: Assistant professor in hematology, Ghazvin University of Medical Science, Ghazvin,Iran.
authors.forename: M
authors.initials: M
authors.lastname: Azad
keywords: 6-Mercaptopurine; 6-Thioguanine; Acute lymphoblastic leukemia; Azathioprine; Myelosuppression; Polymorphism
references.citation: Am J Hum Genet. 1980 Sep;32(5):651-62
references.pmid: 7191632
references.citation: Rev Med Chil. 2009 Feb;137(2):185-92
references.pmid: 19543639
references.citation: Hum Mol Genet. 1999 Feb;8(2):371-6
references.pmid: 9931346
references.citation: Am J Hum Genet. 1996 Apr;58(4):694-702
references.pmid: 8644731
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9394-9
references.pmid: 15967990
references.citation: Clin Pharmacol Ther. 2001 Aug;70(2):165-74
references.pmid: 11503011
references.citation: Biochem Pharmacol. 2008 Oct 15;76(8):1024-35
references.pmid: 18708030
references.citation: Am J Pediatr Hematol Oncol. 1993 Feb;15(1):80-6
references.pmid: 8447563
references.citation: Pharmacogenomics. 2010 Feb;11(2):177-88
references.pmid: 20136357
references.citation: Lancet. 1993 Feb 13;341(8842):436
references.pmid: 8094196
references.citation: Biochem J. 1994 Nov 15;304 ( Pt 1):163-8
references.pmid: 7998928
references.citation: Clin Pharmacol Ther. 2000 Aug;68(2):210-9
references.pmid: 10976552
references.citation: Cancer Res. 2001 Aug 1;61(15):5810-6
references.pmid: 11479220
references.citation: Ann Intern Med. 1998 Nov 1;129(9):716-8
references.pmid: 9841604
references.citation: Blood. 1995 Apr 1;85(7):1897-902
references.pmid: 7703493
references.citation: Hum Mol Genet. 1999 Feb;8(2):367-70
references.pmid: 9931345
references.citation: Pharmacogenetics. 1999 Dec;9(6):773-6
references.pmid: 10634140
references.citation: Cancer Res. 2007 May 15;67(10):4965-72
references.pmid: 17510427
references.citation: Clin Pharmacokinet. 1989 Jun;16(6):327-36
references.pmid: 2661101
references.citation: Science. 1996 Aug 23;273(5278):1109-11
references.pmid: 8688098
references.citation: Clin Pharmacol Ther. 1987 Jan;41(1):18-25
references.pmid: 3467886
references.citation: Lancet. 1990 Jul 28;336(8709):225-9
references.pmid: 1973780
references.citation: Clin Pharmacol Ther. 2011 Mar;89(3):387-91
references.pmid: 21270794
references.citation: Lancet. 1993 May 1;341(8853):1151
references.pmid: 8097831
references.citation: Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6444-9
references.pmid: 9177237
references.citation: Ann Intern Med. 1997 Apr 15;126(8):608-14
references.pmid: 9103127
references.citation: J Mol Biol. 2008 Jun 13;379(4):803-14
references.pmid: 18482735
references.citation: Invest New Drugs. 2005 Dec;23(6):523-32
references.pmid: 16267626
references.citation: Pharmacogenet Genomics. 2005 Nov;15(11):801-15
references.pmid: 16220112
references.citation: Biochemistry. 1997 Mar 4;36(9):2501-6
references.pmid: 9054555
references.citation: Lancet. 1994 May 14;343(8907):1188-90
references.pmid: 7909868
references.citation: Pharm Res. 1999 Mar;16(3):342-9
references.pmid: 10213363
references.citation: J Clin Oncol. 1995 Oct;13(10):2490-6
references.pmid: 7595698
references.citation: Leukemia. 2009 Mar;23(3):557-64
references.pmid: 18987654
references.citation: DNA Cell Biol. 1996 Jan;15(1):17-30
references.pmid: 8561894
references.citation: Pharmacogenet Genomics. 2010 Jun;20(6):401-5
references.pmid: 20154640
references.citation: Arthritis Rheum. 1995 Jan;38(1):142-5
references.pmid: 7818564